Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Eli Lilly & Co. (LLY) announced Friday that it plans to manufacture its experimental weight-loss pill in the U.S. as ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...